Introduction
Compelling evidence exists that indicates that G-proteincoupled receptors (GPCRs) exist as dimers/oligomers that are formed by identical receptor molecules (homomers) or by different receptor molecules (heteromers) as opposed to monomers (Franco et al., 2008) . The criteria to consider a proteinprotein interaction between receptors as a heteromer has been described by Pin et al. (2007) , and the available evidence shows that the assembly between GPCRs is fundamental for many functional aspects of GPCRs; the multimers usually exhibit different properties than the protomers (Terrillon and Bouvier, 2004; Szafran et al., 2013) . The following situations have been associated with the homo-and heteromerization of GPCRs: 1) the interaction between GPCRs is fundamental for the correct functioning of some receptors; 2) the homo-or heteromerization can be constitutive or regulated by a ligand; 3) GPCR assembly can change the pharmacological properties of the individual receptors, as demonstrated by the affinity for a ligand increasing or diminishing and the occurrence of a positive or negative cooperativity between different ligands; 4) a change in signal transduction, either potentiation, attenuation, or changes in the G-protein subfamily coupled to the receptors, can occur in both homomers and heteromers; and 5) endocytosis of some GPCRs can also be affected; the stimulation of one protomer can be sufficient for the internalization of both receptors (Terrillon and Bouvier, 2004) .
In addition to homo-and heteromerization, increasing evidence shows that GPCRs may also interact with the non-GPCR proteins that regulate their trafficking to the plasma membrane and/or their function (McLatchie et al., 1998; Doly and Marullo, 2015) . Evidence showing that GPCRs homo-and heteromerize, and that GPCR interactions with other non-GPCR proteins confers new and different receptor properties, has opened new avenues for the development of more selective pharmacological tools (Rozenfeld and Devi, 2010) .
In this review, we summarize the existing data regarding homo-and heteromerization of corticotropin-releasing factor (CRF) receptors and their interaction with non-GPCR proteins.
Description of the Corticotropin-Releasing Factor System
The CRF system is composed of four neuropeptides: CRF and urocortin 1-3, type-1 (CRF 1 R) and type-2 (CRF 2 R) CRF receptors, and CRF binding proteins (CRF-BPs) (Bale and Vale, 2004; Gysling, 2012) . CRF and urocortin 1 have high affinity for both types of CRF receptors, whereas urocortin 2 and urocortin 3 have high affinity only for CRF 2 R, and CRF and urocortin 1 have high affinity for CRF-BP. Urocortin 2 has low affinity and urocortin 3 has no affinity for CRF-BP (Bale and Vale, 2004) .
The human CRF receptors (CRFRs) are encoded by different genes, but the proteins share high sequence homology (70%). The lowest degree of homology is found in the N-terminal domain (40%) (Dautzenberg and Hauger, 2002) , and many splice variants exist for both receptors. The CRF 1 R cDNA sequence predicts a protein of 415-420 amino acids with one functional and several nonfunctional isoforms (Dautzenberg et al., 2001; Grammatopoulos and Chrousos, 2002) , whereas CRF 2 R has three known functional isoforms. The type-2 a CRF receptor (CRF 2a R) is 411 amino acids in length (Liaw et al., 1996) , and the first 34 amino acids are replaced by a sequence of 61 amino acids in the case of type-2 b CRF receptor (CRF 2b R), which encodes a protein of 438 amino acids (Valdenaire et al., 1997; Grammatopoulos and Chrousos, 2002) . The same 34 amino acids are changed by a sequence of 20 amino acids in the case of the type-2 g CRF receptor (CRF 2g R) protein, which is 397 amino acids long (Kostich et al., 1998) . Besides the N-terminal domain differences, the three CRF 2 R splice variants have different tissue distributions; CRF 2a R is the most abundant isoform in the brain (Dautzenberg and Hauger, 2002; Hauger et al., 2006) , and CRF 2b R is found almost exclusively in peripheral organs and systems, such as the cardiovascular system, intestine, uterus, liver, and placenta (Dautzenberg and Hauger, 2002) .
Homo-and Heteromerization of CRF Receptors
Homodimerization of CRF Receptors. CRF 1 R (Kraetke et al., 2005) and CRF 2b R (Milan-Lobo et al., 2009), but not CRF 2a R (Teichmann et al., 2012) , are capable of homodimerization. CRF 1 R was the first class B GPCR to be described as having the ability to form homomers. Using the methodology of fluorescence resonance energy transfer (FRET) in HEK293T cells, Kraetke et al. (2005) showed that CRF 1 R form homomers in the plasma membrane and in intracellular compartments. Interestingly, the level of CRF 1 R homodimerization was unaffected by the presence of different CRF 1 R agonists, indicating that the homomer assembly does not require a ligand. The presence of homomers in intracellular compartments indicates that their assembly may start intracellularly. As with the GABA B receptor (White et al., 1998) , CRF 1 R homodimerization in intracellular compartments could regulate the presence of CRF 1 R in the plasma membrane. It has also been shown that CRF 2b R homodimerizes in HEK293 transfected cells. Milan-Lobo et al. (2009) compared the homodimerization of CRF 1 R and CRF 2b R and observed that both receptors form homomers in the absence of ligand. Further studies should address the functional consequences of their homodimerization.
CRF 1 R and CRF 2b R differ from CRF 2a R in the structure of the N-terminal extracellular domain. The N-terminal extracellular domain of the three receptors form the same fold, but the CRF 2a R N terminus contains a hydrophobic a-helix formed by its noncleavable pseudosignal peptide, in contrast to CRF 1 R and CRF 2b R, which have a cleavable signal peptide (Rutz et al., 2006; Pal et al., 2010) . The capacity of CRF 1 R and CRF 2a R to form homomers or monomers is due to the absence or presence of the signal peptide, respectively (Fig. 1) . Utilizing chimeras and FRET analyses, Teichmann et al. (2012) elegantly showed that the pseudosignal peptide of CRF 2a R is responsible for the monomeric form of the receptor; the CRF 1 R chimera containing the CRF 2a R noncleavable pseudosignal peptide prevented receptor homodimerization, and the CRF 2a R chimera containing the CRF 1 R cleavable signal peptide was able to homodimerize. Teichmann et al. (2014) showed that CRF 1 R transfected into HEK293T cells exists in the plasma membrane as monomers and homodimers, and that the formation of higher-level oligomers was not observed. In addition, the experiments showed that 22-29% of CRF 1 R present in the plasma membrane was homodimerized, and that this percentage was not modified by the presence of sauvagine, a CRFR agonist.
The ability of CRF 1 R to exist as either a monomer or homodimer could affect its downstream signaling. Schulz et al. (2010) showed that the activation of CRF 1 R yields a biphasic concentration-response curve for cAMP accumulation in the cell, which is generated by the association of the receptor to a G s -protein at low agonist concentration and to a G i -protein at high agonist concentration. On the other hand, CRF 2a R yields a monophasic concentration-response curve for cAMP cell accumulation, which is generated by the association of the receptor to only the G s -protein. These signaling characteristics were transferable when the signal peptide was exchanged, and the biogenesis and the cell surface levels of the CRFRs were also affected (Rutz et al., 2006; Schulz et al., 2010) . The pseudosignal peptide, responsible for the monomeric form of CRF 2a R, leads to an immature nonglycosylated state of the receptor and low levels of CRF 2a R in the cell surface. In contrast, the cleavage of the signal peptide in CRF 1 R leads to high levels of the receptor in the cell surface (Fig. 1) .
Heteromerization of CRF 1 R. There is evidence of heteromerization of CRF 1 R with the vasopressin (AVP) V 1b receptor (V 1b R) (Murat et al., 2012) , the orexin 1 receptor (OX 1 R) (Navarro et al., 2015) , and the 5-hydroxytriptamine (5-HT) receptor (5-HT 2 R) (Magalhaes et al., 2010) . AVP and CRF release adrenocorticotropic hormone (ACTH) from the anterior pituitary, and the receptors involved are V 1b R and CRF 1 R, respectively (Guillon et al., 1987; Liebsch et al., 1999) . Gillies et al. (1982) showed that CRF and AVP have a synergistic effect on the release of ACTH from the pituitary, and Young et al. (2007) , using coimmunoprecipitation (Co-IP) and bioluminescence resonance energy transfer (BRET) techniques, showed that V 1b R and CRF 1 R are able to interact in Chinese hamster ovary cells. The interaction of V 1b R and CRF 1 R is not dependent on the presence of their agonists, suggesting that their heteromerization is constitutive and not a process regulated by their ligands. The presence of agonists for V 1b R and CRF 1 R does not modify the number of receptors that bind to their ligands in the plasma membrane. Murat et al. (2012) addressed the question of how the synergistic action of AVP and CRF takes place in the pituitary. These authors documented the heteromerization of V 1b R with CRF 1 R using BRET, Co-IP, and receptor rescue experiments, and showed that the activation of either V 1b R or CRF 1 R, naturally expressed in bovine chromaffin cells, was able to induce catecholamine secretion. Interestingly, the coinfusion of both agonists induced a synergistic action on catecholamine secretion. Considering the evidence presented earlier, it is clear that the presence of the V 1b R/CRF 1 R heteromer is crucial for the synergistic effect of AVP and CRF for releasing ACTH. The functional relevance of this heteromer may explain the observations made in knockout mice for V 1b R (Tanoue et al., 2004) ; in these mice, the circulating levels of ACTH were lower at resting conditions and under stress induced by forced swimming (Tanoue et al., 2004) .
CRF plays a key role in the plastic changes associated with stress and drug abuse (Shaham et al., 1998; Ungless et al., 2003; Williams et al., 2014; Zorrilla et al., 2014; Sotomayor-Zárate et al., 2015) . CRF 1 R is involved in the sensitization of dopaminergic neurons by CRF in the ventral tegmental area (VTA) after cocaine administration and in stress-induced relapse to cocaine seeking (Hahn et al., 2009; Blacktop et al., 2011) . The neuropeptide orexin-A (OX-A) has also been involved in relapse to cocaine seeking (Boutrel et al., 2005) . Relapse was prevented by a nonselective antagonist of CRF receptors and a selective antagonist of the OX 1 R. Wang et al. (2009) reported that VTA CRF and OX-A were involved in stress-induced relapse to cocaine seeking by independent mechanisms. Navarro et al. (2015) investigated whether CRF 1 R and OX 1 R were able to form heteromers in cell lines and in vivo, and obtained compelling evidence of the heteromerization of CRF 1 R and OX 1 R that determines a negative cross-talk between both receptors. The use of peptides bearing the sequence of transmembrane domains, TM1 and TM5 of OX 1 R, allowed the disassembly of the heteromer and consequently the negative cross-signaling between both receptors, confirming that the integrity of the heteromer is crucial for the cross-talk between the receptors. Interestingly, the negative cross-talk between CRF 1 R and OX 1 R was also observed in VTA slices. CRF 1 R signals through G s -protein, increasing cAMP production, whereas OX 1 R signals though G i -protein, decreasing cAMP synthesis. The infusion of an antagonist for one of the receptors antagonized the cAMP effect of the agonist for the other receptor. The negative cross-talk between CRF and OX-A was perceived not only at the level of second messengers, but also at the level of dopamine release. The release of dopamine in the VTA was antagonized by infusing antagonists for CRF 1 R and OX 1 R, but was recovered by infusing the agonists for the receptors in the VTA. Therefore, the CRF 1 R/OX 1 R heteromer is present in the VTA and plays a role in controlling dopamine release. Further studies should address the apparent discrepancies between this work and the independent control exerted by CRF and OX-A previously described (Wang et al., 2009 ). Navarro et al. (2015) also found that the s1 receptor (s 1 R) was able to oligomerize with the CRF 1 R/OX 1 R heteromer, specifically with CRF 1 R. The activation of s 1 R eliminates the negative cross-talk between CRF and OX-A in the VTA (Navarro et al., 2015) . It is tempting to suggest that the activation of s 1 R may explain the apparent differences between the work of Wang et al. (2009) and that of Navarro et al. (2015) . It was stated that cocaine is an agonist for s 1 R (Kourrich et al., 2012) , and this evidence suggests that the CRF 1 R/s 1 R/OX 1 R oligomer may be a potential target for the pharmacological treatment of addiction.
The CRF system also plays a key role in anxiety disorders, such as depression (Reul and Holsboer, 2002; Kehne, 2007) . CRF and 5-HT are known to influence and modulate depressive and anxiety-like behaviors (Müller et al., 2003; Bockaert et al., 2006) , and Tan et al. (2004) demonstrated that the activation of CRF 1 R in neurons of the prefrontal cortex (PFC) results in the modulation of 5-HT 2 R signaling. The sIPSC in the PFC were increased by stimulation with 5-HT in PFC slices pretreated with CRF or obtained from stressed animals, suggesting that CRF 1 R and 5-HT 2 R may interact in the PFC. Magalhaes et al. (2010) showed that the activation of CRF 1 R increased inositol phosphate formation induced by the activation of 5-HT 2 R in heterologous cell cultures as well as in mouse cortical neurons. The increase in inositol phosphate produced by pretreatment with CRF is not due to CRF 1 R activation; the stimulation of CRF 1 R alone does not lead to the formation of inositol phosphate. Interestingly, when the cells were first pretreated with 5-HT and thereafter with a CRF 1 R agonist, no significant increase in cAMP production in response to the activation of CRF 1 R was observed. Thus, the synergistic effect between both receptors is observed only when CRF 1 R is stimulated before 5-HT 2 R. The functional consequence of the CRF 1 R/5-HT 2 R interaction is that previous exposure of the prefrontal cortex to CRF increases 5-HT 2 -dependent behavior induced by 2,5-dimethoxy-4-iodoamphetamine (Magalhaes et al., 2010) . Magalhaes et al. (2010) found that a subpopulation of neurons in the PFC express the CRF 1 and 5-HT 2A receptors. In the presence of CRF, both receptors underwent endocytosis and were located in intracellular vesicles. Subsequently, it was observed that the endocytosis and recycling of CRF 1 R were essential for the synergism between CRF 1 R and 5-HT 2 R. These authors also indicated that the interaction between 5-HT 2 R and CRF 1 R occurs through their PSD95/discs large/occludens zone 1 domains (PDZ)-binding domains in the carboxyl-terminal domain of both receptors. This is one of the critical differences between CRF 1 R and CRF 2 R, because the class I PDZ binding domain (STAV) is only found in CRF 1 R (Fig. 1) . Therefore, CRF 1 R, but not CRF 2a R or CRF 2b R, is able to interact with 5-HT 2 R. Interestingly, it was proposed that this interaction is not direct and depends on a PDZ domain containing protein (Magalhaes et al., 2012) . PDZ domains are usually the sites of interaction of non-GPCR proteins with GPCRs.
Heteromerization of CRF 2 R. At present, there is only evidence of the heteromerization of CRF 2a R with the dopamine type-1 receptor (D 1 R) (Fuenzalida et al., 2014) , and this heteromer assembles in the absence of ligands. The evidence was obtained in HEK293T cells cotransfected with the receptors using FRET, BRET, Co-IP, and homogeneous timeresolved fluorescence to measure cAMP accumulation in the cells. It was also observed that the CRF 2a R/D 1 R heteromer had a number of characteristics that were different from the protomers. First, the subcellular localization of the receptors changed. The D 1 R is located mainly in the cell surface (O'Dowd et al., 2005) and CRF 2a R intracellularly (Waselus et al., 2009; Wood et al., 2013) . However, when the receptors are coexpressed, the D 1 R is found mostly in the endoplasmic reticulum (ER) colocalizing with CRF 2a R. Second, the signaling properties also changed. CRF 2a R and D 1 R couple to G s -protein, resulting in intracellular cAMP accumulation (Dautzenberg and Hauger, 2002; Neve et al., 2004) , and the CRF 2a R/D 1 R heteromer maintained the signaling through cAMP upon stimulation with CRF 2a R and D 1 R agonists. However, the protein was also able to mobilize intracellular calcium upon stimulation with D 1 R agonist. Moreover, synergism was described between CRF 2a R and D 1 R in the synaptic transmission from rat basolateral amygdala to the PFC (Orozco-Cabal et al., 2008) . Utilizing electrophysiological approaches, the authors showed that the activation of either of these receptors increases cocaine-induced synaptic depression. When both receptors were activated, a positive cooperativity between both ligands was observed on synaptic depression. Moreover, after chronic cocaine use, the activation of both receptors induced synaptic facilitation; these results led the authors of the study to propose the existence of heteromers between dopamine and CRF receptors (Orozco-Cabal et al., 2008) .
CRF Receptors and Their Interaction with Non-GPCR Proteins
Compelling evidence exists showing that GPCRs interact with specific non-GPCR proteins, and these interactions are very important in the regulation of the trafficking, maturation, cell surface expression, signaling, and/or desensitization of the receptors. These interacting proteins are called accessory or escort proteins (Achour et al., 2008; Roux and Cottrell, 2014) .
Formerly, it was believed that GPCRs were found mainly in the plasma membrane ready to be activated by their ligands. It is now known that most GPCRs accumulate as stock of functional receptors, or ready to finish maturation, in the ER or Golgi apparatus, and they traffic to the plasma membrane when needed (Achour et al., 2008; Doly and Marullo, 2015) . Two types of proteins, the gatekeepers and the escort proteins, jointly regulate the push and pull from the ER or Golgi apparatus to the plasma membrane. The gatekeepers are ER or Golgi apparatus resident proteins that interact and retain GPCRs in the respective cellular compartment. The release of the GPCRs from the ER or Golgi apparatus occurs only after a competitive displacement of the GPCR/gatekeeper interaction by a GPCR/escort protein interaction (Doly and Marullo, 2015) .
Recently, the existence of CRFR escort proteins has been described. The receptor activity-modifying protein 2 (RAMP2), one of the most studied escort proteins, functions as a CRF 1 R escort protein, modifying cell surface expression and signaling of the receptor (Wootten et al., 2013) . Using heterologous expression in cell cultures and enzyme-linked immunosorbent assays to measure plasma membrane protein expression, Wootten et al. (2013) determined that RAMP2 increases the plasma membrane expression of CRF 1 R. In addition, measuring cAMP production, calcium mobilization, and CRF 1 R/guanosine 59-3-O-(thio) triphosphate binding, the authors showed that RAMP2 did not affect the ability of CRF 1 R to bind G s -protein or of CRF 1 R agonists to stimulate cAMP production. Instead, it generated an increase in the ability of CRF 1 R to bind G i/o/t/z -, G q/11 -, and G 12/13 -proteins, and CRF 1 R was now able to mobilize intracellular calcium.
Recently, it was shown that CRF-BP functions as a CRF 2a R escort protein (Slater et al., 2016b) . Using yeast two-hybrid assay and Co-IP in HEK293T cells extracts transfected with the corresponding proteins, it was shown that CRF-BP physically interacts with CRF 2a R in an isoform-specific manner, and using confocal microscopy, it was determined that CRF-BP increases CRF 2a R plasma membrane levels (Slater et al., 2016b) . Moreover, endogenous CRF-BP and CRF 2a R colocalize in cultured mesencephalic neurons (Slater et al., 2016b) and coexist in VTA synaptosomes (Slater et al., 2016a) . Thus, this anatomic evidence indicates that CRF-BP and CRF 2a R coexist in pre-and postsynaptic elements in the VTA.
CRF 2a R is expressed mainly in the ER (Fuenzalida et al., 2014; Slater et al., 2016b) , where it is retained due to its described interaction with the ER resident protein calnexin (Schulz et al., 2010) . Calnexin interacts with the CRF 2a R pseudosignal peptide (Schulz et al., 2010) , and CRF-BP interacts with the N-terminal domain of CRF 2a R (Slater et al., 2016b) . Thus, it is tempting to suggest that a competitive displacement of the CRF 2a R/calnexin interaction by CRF-BP is necessary for the receptor to reach the plasma membrane.
Furthermore, there is evidence of a glutamate neurotransmission potentiation role of CRF-BP over CRF signaling through CRF 2 R, both presynaptically (Wang et al., 2005 (Wang et al., , 2007 and postsynaptically (Ungless et al., 2003) , in the VTA after cocaine experience or stress. Further studies are necessary to determine whether the interaction between CRF 2a R and CRF-BP is related to the requirement of the CRF interaction with CRF-BP to potentiate this addictive and stress-related neuronal plasticity.
In addition, a family of synaptic proteins known as membrane-associated guanylate kinases (MAGUKs) is important for the assembly and signaling of other proteins. MAGUK proteins contain PDZ domains, which can interact with a variety of proteins. The interaction of MAGUK proteins with multiple receptors occurs through binding to the PDZ motifs present in the carboxyl-terminal domain of the receptors (Kim and Sheng, 2004; Dunn and Ferguson, 2015) .
CRF 1 R interacts with several MAGUK proteins: PSD95, PSD93, SAP102, SAP97, and MAGI2 (Dunn et al., 2013 (Dunn et al., , 2016 Walther et al., 2015) . Dunn et al. (2013) showed the interaction between CRF 1 R and SAP97, an interaction dependent on the CRF 1 R PDZ domain that is not modified in the presence of agonists, such as CRF. Furthermore, SAP97 attenuates CRFinduced endocytosis of CRF 1 R, maintaining a higher level of CRF 1 R in the plasma membrane. On the other hand, the MAGUK protein PDZK1 interacts with CRF 1 R, increasing extracellular signal-related kinase 1/2 signaling (Walther et al., 2015) . PSD95 also interacts with CRF 1 R, and similar to SAP97, PSD95 attenuates ligand-induced endocytosis of CRF 1 R. However, PSD95 does not detectably alter CRF 1 R signaling (Dunn et al., 2016) . CRF 1 R has an STAV in its C-terminal domain (Magalhaes et al., 2010) . Bender et al. (2015) , using yeast two-hybrid assays and Co-IP in HEK293 cells and neuronal cultures, as well as the modification of the STAV sequence of CRF 1 R, documented that it is the C-terminal domain of CRF 1 R that interacts with the PDZ domains of MAGUK proteins. Therefore, although CRF 1 R has a PDZbinding domain that can interact with various MAGUK proteins, not all MAGUK proteins regulate CRF 1 R in the same way.
After their agonists activate GPCRs, a process of desensitization occurs, which consists of preventing the GPCR/G-protein interaction followed by the endocytosis of the receptors. Usually, the desensitization process occurs due to the GPCR interacting protein, b-arrestin. The phosphorylation of the receptor by the GPCR kinases is necessary for its interaction with b-arrestins and for targeting clathrin-coated pits for endocytosis (Kohout and Lefkowitz, 2003) . Both CRF 2 R and CRF 1 R have a high degree of sequence conservation of consensus sites for phosphorylation by several protein kinases, which could modulate CRFR function (Hauger et al., 2006) . CRF 1 R is capable of recruiting b-arrestin 1 (Rasmussen et al., 2004 ) and b-arrestin 2 (Perry et al., 2005) . Using confocal microcopy, Rasmussen et al. (2004) demonstrated that treatment with kinase inhibitors affects the recruitment of b-arrestin 1, but not CRF 1 R internalization. Thus, b-arrestin 1/CRF 1 R interaction is not necessary for CRF 1 R endocytosis in HEK293 cells. Similarly, b-arrestin 1 proteins do not internalize with CRF 1 R in primary cortical neurons (Holmes et al., 2006) . Perry et al. (2005) showed that CRF 1 R is able to recruit b-arrestin 2 in HEK293 cells and in primary cortical neurons. Moreover, b-arrestin 2 internalizes with CRF 1 R in HEK293 cells, but not in cortical neurons. Using confocal microscopy, Hauger et al. (2013) demonstrated that CRF 2a R can also recruit b-arrestin 2 in HEK293 cells in an agonist concentration-dependent manner, but they reported that b-arrestin 2 is not internalized with CRF 2a R. Furthermore, Milan-Lobo et al. (2009) showed that both CRF 2b R and CRF 1 R homomers recruited b-arrestin upon agonist stimulation. However, they observed that CRF 1 R, and not CRF 2b R, was internalized. The available data for CRFR interacting proteins have been obtained with heterologous overexpression of the interacting partners. Protein overexpression could lead to nonphysiologic protein/protein interactions. Due to the potential relevance of these interactions, they should be studied in physiologic/physiopathologic states.
Conclusions
Increasing evidence shows that CRF receptors interact with themselves to form homomeric dimers (CRF 1 R and CRF 2b R) and with other GPCRs to form heteromers (CRF 1 R and CRF 2a R) (Fig. 1 ). At present, there is no evidence showing the interaction of CRF 2b R with other GPCRs. In addition, CRF receptors interact with non-GPCR proteins that regulate their localization in the plasma membrane. CRF 1 R interacts with membrane-associated guanylate kinases, as well as with receptor activity-modifying protein 2 to increase its presence in the plasma membrane. CRF 2a R, but not CRF 2b R, interacts with CRF-BP, which facilitates its access to the plasma membrane. The interaction of these proteins has been observed only in heterologous overexpression assays. However, the anatomic evidence of their coexistence in specific neuronal phenotypes demands further in vivo studies to elucidate the potential contribution of the reviewed protein interactions in the stress response in health and disease. For instance, the reported interaction of CRF 2a R with D 1 R and with CRF-BP may occur in the ventral tegmental area as well as in other brain regions involved in the interaction between stress and addiction. As proposed by Arzt and Holsboer (2006) , selective signaling of CRF-R1 in different brain regions could be exploited to generate new pharmacological strategies to treat stress-related disorders. It is tempting to suggest that the differential signaling of CRF-R1 in different brain regions could be due to their interactions with other GPCRs or non-GPCR proteins. Thus, a better knowledge of such interactions and their functional consequences may open new pharmacological strategies to treat addictive behavior and stress-related disorders.
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